Earnings

Checking Out the Fundamental Data for Intrepid Potash, Inc. (IPI)

Intrepid Potash, Inc. (NYSE:IPI) seems to be forming a pattern of major movements, providing only some crumbs of outlook for market participants trying to figure out its next move. Now trading with a market value of 508.94M, the company has a mix of catalysts and obstacles that spring from the nature of its operations. In light of the many issues surrounding this company, we thought it was a good time to take a close look at the numbers in order to form a realistic perspective on the fundamental picture for this stock.

Intrepid Potash, Inc. (NYSE:IPI) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For IPI, the company currently has 6.19 million of cash on the books, which is offset by 6 million in current liabilities. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 506.08 million in total assets, balanced by 103.31 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

Intrepid Potash, Inc. (IPI) saw 8.56 million in free cash flow last quarter, representing a quarterly net change in cash of -14.58 million. Perhaps most importantly where cash movements are concerned, the company saw about 9.69 million in net operating cash flow.



Intrepid Potash, Inc. (NYSE:IPI) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 43.91 million in total revenues. That represents a quarterly year/year change in revenues of -0.15 in sequential terms, the IPI saw sales decline by -0.09.

But what about the bottom line? After all, that’s what really matters in the end. Intrepid Potash, Inc. (IPI) is intriguing when broken down to its core data. The cost of selling goods last quarter was 40.6 million, yielding a gross basic income of 3.31 million. For shareholders, given the total diluted outstanding shares of 126.22 million, this means overall earnings per share of -0.05. Note, this compares with a consensus analyst forecast of -0.04 in earnings per share for its next fiscal quarterly report.




Is Intrepid Potash, Inc. (NYSE:IPI) Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about 0.04 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 360.69. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Intrepid Potash, Inc..

Previous ArticleNext Article

Related Post

Castlight Health, Inc. (CSLT) Just Flashed an Extr... Castlight Health, Inc. (NYSE:CSLT) fell by -6.41% in yesterday’s trading from $3.90 to $3.65 and has now fallen 4 consecutive sessions. The price has ...
A Side-by-side Analysis of Glacier Bancorp, Inc. (... Glacier Bancorp, Inc. (NASDAQ:GBCI) shares are up more than 5.40% this year and recently decreased -1.44% or -$0.55 to settle at $37.54. First Interst...
What Recent Ownership Trends Suggest About Synthet... Recent insider trends for Synthetic Biologics, Inc. (NYSE:SYN) have caught the attention of investors. Analysts study insider data to get a sense of s...
Critical Comparison: Twenty-First Century Fox, Inc... Twenty-First Century Fox, Inc. (NASDAQ:FOXA) shares are up more than 2.46% this year and recently increased 2.50% or $0.7 to settle at $28.73. Time Wa...
Comparing CVS Health Corporation (CVS) and UnitedH... CVS Health Corporation (NYSE:CVS) shares are down more than -10.73% this year and recently decreased -1.45% or -$1.04 to settle at $70.44. UnitedHealt...